Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL782541 | 0.94 | KMT2A (0.31) | KMT2A | |
| SCHEMBL782586 | 0.93 | CRHR1 (0.34) | TP53POLBALDH1A1 | |
| SCHEMBL782286 | 0.93 | KMT2A (0.33) | KMT2AMEN1L3MBTL1TP53ALDH1A1 | |
| SCHEMBL782392 | 0.92 | HSD11B1 (0.33) | KMT2AMEN1MAPK1L3MBTL1TP53 | |
| SCHEMBL782511 | 0.92 | HDAC3 (0.33) | KMT2AMEN1MAPK1L3MBTL1TP53 | |
| SCHEMBL782336 | 0.92 | KCNH2 (0.31) | L3MBTL1TP53ALDH1A1KCNH2 | |
| SCHEMBL782417 | 0.91 | TP53 (0.31) | KMT2AL3MBTL1TP53ALDH1A1NPY5R | |
| SCHEMBL782555 | 0.91 | — | — | |
| SCHEMBL782580 | 0.91 | ALDH1A1 (0.33) | KMT2AMEN1L3MBTL1TP53POLB | |
| SCHEMBL782396 | 0.89 | HDAC3 (0.31) | KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8574607-B2 | Spiroheterocyclic thiofuran dione derivatives | SYNGENTA CROP PROTECTION, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8574607-B2 | Spiroheterocyclic thiofuran dione derivatives | SYNGENTA CROP PROTECTION, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8574607-B2 | Spiroheterocyclic thiofuran dione derivatives | SYNGENTA CROP PROTECTION, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| WO-2012069008-A1 | 3-SUBSTITUTED SPIROHETEROCYCLIC FURAN AND THIOFURAN DIONE DERIVATIVES USEFUL AS PESTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-05-31 | — | — | WO | disclosed |
| US-20120071319-A1 | SPIROHETEROCYCLIC FURAN AND THIOFURAN DIONE DERIVATIVES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071319-A1 | SPIROHETEROCYCLIC FURAN AND THIOFURAN DIONE DERIVATIVES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071319-A1 | SPIROHETEROCYCLIC FURAN AND THIOFURAN DIONE DERIVATIVES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2010135914-A1 | NEW SPIROHETEROCYCLIC FURAN AND THIOFURAN DIONE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010135914-A1 | NEW SPIROHETEROCYCLIC FURAN AND THIOFURAN DIONE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071319-A1 | SPIROHETEROCYCLIC FURAN AND THIOFURAN DIONE DERIVATIVES | DDT, DHFR, CYP1A1 | KMT2A 4234/4885MEN1 1302/4885MAPK1 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.